Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients

Targeting epidermal growth factor receptor (EGFR) has been one of the most effective colorectal cancer strategies. Anti-EGFR antibodies function by binding to the extracellular domain of EGFR, preventing its activation, and ultimately providing clinical benefit. KRAS mutations in codons 12 and 13 ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Er, Tze-Kiong, Chen, Chih-Chieh, Bujanda, Luis, Herreros-Villanueva, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086227/
https://www.ncbi.nlm.nih.gov/pubmed/25032217
http://dx.doi.org/10.1155/2014/591867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086227/
https://www.ncbi.nlm.nih.gov/pubmed/25032217
http://dx.doi.org/10.1155/2014/591867

Ejemplares similares